Evidence map›Paper›PMID 42457984›Full record

ArticleBone marrow transplantation2026

Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.

Jule Ussmann, Madlen Jentzsch, Sebastian Schwind, Marco Herling, Vladan Vučinić, Maximilian Merz, Inken Hilgendorf, Andreas Hochhaus, Uwe Platzbecker, Klaus H Metzeler and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jule UssmannDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany. jule.ussmann@medizin.uni-leipzig.de.ORCID http://orcid.org/0009-0008-8387-2889
Madlen JentzschDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.ORCID http://orcid.org/0000-0002-2270-0804
Sebastian SchwindDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.ORCID http://orcid.org/0000-0002-1315-2332
Marco HerlingDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Vladan VučinićDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.ORCID http://orcid.org/0000-0002-8398-285X
Maximilian MerzDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
Inken HilgendorfCCCG, Cancer Center Central Germany, Leipzig/Jena, Germany.ORCID http://orcid.org/0000-0003-2038-9730
Andreas HochhausCCCG, Cancer Center Central Germany, Leipzig/Jena, Germany.
Uwe PlatzbeckerUniversity Hospital of Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0003-1863-3239
Klaus H MetzelerDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.ORCID http://orcid.org/0000-0003-3920-7490
Georg-Nikolaus FrankeDepartment for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42457984
PMCPMC13569441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.